Acumenta Releases Term Viewer to Literature Lab™ Users

Boston, MA – November 4, 2008: Acumenta Corporation (www.acumenta.com) announces delivery of the Literature Lab™ Term/Genes Viewer to non-profit users of Literature Lab™, Acumenta’s literature mining-based gene set enrichment solution. It is licensed to institutions that provide Literature Lab™ analyses to their investigators.

The Term/Genes Viewer is a general reference tool that makes use of three Literature Lab™ components: the Acumenta Gene Thesaurus™, the Literature Lab™ Base Data set and the Literature Lab™ Results Viewer. Empowered by the Gene Thesaurus™, the Term/Genes Viewer enables scientists to quickly explore relationships among terms and genes. With a few mouse clicks a scientist can select any two terms from the 18 Literature Lab™ domains (a total of 78,000 biochemical terms), instantly review literature relevant to the two terms and get a list of genes mentioned in the literature with the terms. For example, the answer to a question like: “which genes are prominently associated in the literature with multiple myeloma and neoplasm invasiveness” is instantly available.

Acumenta’s Literature Lab™ is a literature mining solution for scientists in academic/research institutions and biotech and pharmaceutical companies. It enriches gene lists in 18 biochemical domains including pathways, diseases, compounds/drugs, metabolism and cell biology, solving two major challenges shared by virtually all investigators whose work involves microarray analysis and other genomic experimentation:

Gaining a thorough understanding of the biology associated with experimentally-derived gene lists.
Keeping up with the constant deluge of new scientific literature and using it to accelerate their research.

Literature Lab™ is the first commercially available turnkey commercial software application to simplify and deliver powerful automated literature mining to every investigator. Scientists use the Literature Lab™ Results Viewer, an extremely easy to use exploration tool, to explore the results of Literature Lab™ analyses, glean biological insight and identify new testable hypotheses.

“Scientists all too often get a gene list at the end of a microarray analysis pipeline and aren’t able to understand the biological significance of the gene set as a set,” said Stephen C. Taylor, Acumenta’s CEO and chief architect of Literature Lab™. “They end up exploring a single marker or pathway without understanding the subtle impact of other genes in the data set.”

“Literature Lab™ is a significant addition to a scientist’s repertoire of tools that help to accelerate drug discovery research,” said Paul R. Martinez, Acumenta's Vice President of Sales and Marketing. “Literature Lab™ mines over 9.7 million PubMed abstracts to help scientists infer biology from microarray data and other gene lists of interest.”

Founded in 2001, Acumenta Corporation is based in Boston, Massachusetts. Acumenta is a software and information company serving biotechnology and pharmaceutical firms and non-profit research organizations. Acumenta builds applications on the Acumenta platform that automate information gathering, analysis and management tasks associated with Web-based and proprietary external and internal databases. Acumenta's curated Thesaurus of Gene and Protein Nomenclature and software products improve both the efficiency and quality of research in the life sciences R&D function.

Contact: Paul Martinez
Title: Vice President Sales & Marketing
Phone: 617-379-0691
Email: pmartinez@Acumenta.com
URL: www.Acumenta.com

[ back to top ]